Randomised trials comparing chemotherapy regimens for advanced non-small cell lung cancer: biases and evolution over time
| dc.contributor.author | Ioannidis, J. P. | en |
| dc.contributor.author | Polycarpou, A. | en |
| dc.contributor.author | Ntais, C. | en |
| dc.contributor.author | Pavlidis, N. | en |
| dc.date.accessioned | 2015-11-24T18:55:06Z | |
| dc.date.available | 2015-11-24T18:55:06Z | |
| dc.identifier.issn | 0959-8049 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/18807 | |
| dc.rights | Default Licence | - |
| dc.subject | Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | en |
| dc.subject | Carcinoma, Non-Small-Cell Lung/*drug therapy | en |
| dc.subject | Humans | en |
| dc.subject | Lung Neoplasms/*drug therapy | en |
| dc.subject | *Randomized Controlled Trials as Topic | en |
| dc.subject | Selection Bias | en |
| dc.subject | Survival Analysis | en |
| dc.title | Randomised trials comparing chemotherapy regimens for advanced non-small cell lung cancer: biases and evolution over time | en |
| heal.abstract | We systematically evaluated the evidence from randomised trials comparing various chemotherapy regimens for advanced non-small cell lung cancer. Across 254 eligible trials (42661 patients), no regimens were compared in >6 studies. Twenty-six trials (10%) found statistically significant differences in survival between the compared arms. Only five reported the randomisation mode, and four reported adequate allocation concealment; nine performed unaccounted interim analyses. Statistical significance was more common in larger (P=0.003), more recent studies (P=0.031), and trials from countries with only one published eligible study (P=0.008). Increased reported median survival was independently associated with platinum and/or taxane and combination regimens, but also with the year of publication, smaller sample size, and larger representation of non-stage IV patients and patients with a better performance status. The proportion of enrolled patients with a performance status of 2 or worse decreased significantly over time (12.9% per decade, P<0.001). Randomised evidence in this field is fragmented and subject to considerable selection biases. | en |
| heal.access | campus | - |
| heal.fullTextAvailability | TRUE | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/14556918 | - |
| heal.identifier.secondary | http://ac.els-cdn.com/S0959804903005719/1-s2.0-S0959804903005719-main.pdf?_tid=a4dc3aed39590beb3a31a127592c1baa&acdnat=1333611574_f3fe34710da4b3e912ff4ad2bf1eed94 | - |
| heal.journalName | Eur J Cancer | en |
| heal.journalType | peer-reviewed | - |
| heal.language | en | - |
| heal.publicationDate | 2003 | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.type | journalArticle | - |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.type.en | Journal article | en |
Αρχεία
Φάκελος/Πακέτο αδειών
1 - 1 of 1
Φόρτωση...
- Ονομα:
- license.txt
- Μέγεθος:
- 1.74 KB
- Μορφότυπο:
- Item-specific license agreed upon to submission
- Περιγραφή: